Moreover, regarding one of identified presumable ALDH+CSC-like populations of RCC, anti-angiogenic Sorafenib treatment induced a 2–3 fold increase in a number of ALDH+ ACHN cells as compared with normal conditions [72]. Here, LDHA is linked to renal cell carcinoma.